Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
InnoCIMAb
Singapore, Singapore
- Ownership
- Private
- Development stage
- Other
01
Overview
InnoCIMAb is a Singapore-based biotechnology joint venture established between the Center of Molecular Immunology (CIM) in Cuba and Inno-Gene Holdings. The company focuses on the development, manufacturing, and commercialization of therapeutic monoclonal antibodies for the treatment of cancer and other chronic diseases. Its lead product is Nimotuzumab, a humanized monoclonal antibody targeting the epidermal growth factor receptor (EGFR), which is approved in multiple territories for various oncology indications. InnoCIMAb serves as a strategic hub for clinical development and market expansion of CIM's portfolio in the Asia-Pacific region and beyond.
- Therapeutic areas
- Oncology
- Modalities
- Monoclonal antibodyBiologic
- Industry
- Biotech
02
Partnerships
Center of Molecular Immunology (CIM)Inno-Gene HoldingsBioconDaiichi Sankyo
Beyond the preview
Go deeper on InnoCIMAb.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on InnoCIMAb.